2023年3月17日,

协同医疗赢得声望的大奖赛GALIEN在比利时的光电inc .提供的新闻分享本文协同医疗赢得比利时大奖赛GALIEN 2023年承诺设备奖协同医疗高兴地宣布,他们已经获得了大奖赛GALIEN 2023年在比利时有前途的医疗设备。陪审团的认可,我们的设备有可能带来突破治疗许多癫痫患者生活在恐惧的癫痫发作是极其令人鼓舞”,阿提拉Borbath增效的CEO和创始人医疗比利时,3月17日2023 / EINPresswire.com——协同医疗发达NAO临床医疗设备公司。迷走神经刺激法,第一光电设备日前通过迷走神经刺激治疗癫痫耐药,高兴地宣布,他们已经获得了大奖赛Galien 2023年在比利时有前途的医疗设备。“我很高兴所有的团队协作医疗赢得了这个著名的和世界知名的奖项。陪审团的认可,我们的设备有可能带来突破治疗许多癫痫患者癫痫发作的生活在持续的恐惧是非常令人鼓舞的。很荣幸获得这个奖项后不久被欧盟共同选定加速器项目。”阿提拉Borbath,协同医疗的CEO和创始人。“在操作方面,我们最近完成了临床前安全性研究成功非常有前途的结果。我们现在专注于准备First-In-Human研究中,预定明年,我们在美国食品药品管理局申请。”他补充道。关于大奖赛Galien米娜Galien成立于1970年由罗兰为了纪念Galien梅尔,医学和现代药理学的父亲。全世界大奖赛Galien被认为是诺贝尔奖的生物制药的研究。在比利时大奖赛的Galien由“《医生。” About Epilepsy and Drug-Resistant Epilepsy Epilepsy is the 4th most common neurological disorder after migraine, stroke, and Alzheimer’s disease affecting 65 million people worldwide. The conventional medical treatment is with anti-epileptic drugs (AEDs) but 30% of the epileptic population see their symptoms poorly controlled with drugs and continue to have seizures that impair their health and daily life despite medication intake. They are consequently diagnosed with DRE (drug-resistant epilepsy). More than 1.15 million patients are currently waiting for an effective treatment, representing an estimated obtainable market of c.€20 billion. Development update of NAO.VNS – Optoelectonics for Vagus Nerve Stimulation NAO.VNS is a new generation neurostimulator that can reduce drug-resistant epileptic seizures by stimulation of the vagus nerve (VNS), using a new technology of materials to improve patients’ life. Neural stimulation is a clinically proven solution and the last resort for these patients. It involves the implantation of a small pacemaker connected to leads that deliver mild electric signals to the targeted nerve. NAO.VNS uses optical fibers and quartz, instead of metal wires and casing. Optoelectronics enables safe, personalized neural stimulation pulses in a magnetic field and renders NAO.VNS fully compatible with MRI or brain scans. The first in-vivo health and environmental safety study was successfully completed at the end of 2022. About Synergia Medical – www.synergia-medical.com Synergia Medical is an ISO 13485 certified medical device company that has developed NAO.VNS (Vagus Nerve Stimulation), the first optoelectronic neurostimulator for the treatment of drug-resistant epilepsy. Operational since 2016, Synergia Medical is based in Belgium and employs 30 employees. It was co-founded by Attila Borbath, CEO and Pascal Doguet, inventor of NAO.VNS. The company holds a portfolio of 9 patents in 15 families. James Palmer